Not exact matches
A Phase II Single - Arm Trial to Investigate Tepotinib in advanced (
Stage IIIB / IV) Non-Small
Cell Lung Cancer with MET Exon 14 (METex14) Skipping Alterations After Failure of at Least One
Prior Active Therapy, Including a Platinum - Doublet - Containing Regimen
The FDA granted approval to durvalumab (IMFINZI ®, AstraZeneca), a checkpoint immunotherapy that targets the PD - 1 / PD - L1 pathway, for patients with unresectable,
stage III non-small
cell lung cancer (NSCLC) that hasn't progressed after
prior chemo - radiation treatment.
For more information regarding Bristol - Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: • Early
stage IB - IIIA, operable non-small
cell lung cancer, confirmed in tissue • Lung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease •
Prior treatment with any drug that targets T
cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could apply
Inclusion Criteria: • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 • Have histologically or cytologically confirmed advanced or metastatic non-small
cell lung cancer (NSCLC)(
Stage IIIb or greater) • Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 • Known PD - L1 tumor status as determined by an immunohistochemistry (IHC) assay performed by the central laboratory on tissue obtained at Screening • A woman of childbearing potential must have a negative highly sensitive serum (beta - human chorionic gonadotropin [beta - hCG]-RRB- at Screening within 14 days
prior to study drug administration Inclusion Criteria for Crossover: • Participants must have been randomized to Arm A of the study and had radiographic disease progression according to RECIST 1.1 • Participants must have a mandatory biopsy at the time of disease progression according to RECIST 1.1
prior to crossing over.
Unexpectedly, we observed that, even
prior to reprogramming, the HUF1 line possessed
cells that demonstrated heterogeneous expression of
stage specific embryonic antigen 3 (SSEA3; Figure 1B).
Third, wild - type and toddler mutant embryos were injected at the one
cell stage with increasing levels of Nodal mRNA and Nodal target gene expression was measured just
prior to gastrulation using qRT - PCR.
Any type of prognosis for the effectiveness of treatment and the future of the disease depends upon different and varying criteria including a tumor's resistance to treatment, the
cell type of the tumor, tumor
stage and size, and how much the tumor has progressed
prior to detection.